Kerala Ayurveda Reports Strong H1 Growth, Unveils Vision 2030

Kerala Ayurveda Limited (KAL), a leading Ayurvedic healthcare company, has reported a 27% revenue growth in the first half of the fiscal year, with revenues reaching Rs. 74.62 crores. The company has also announced its Vision 2030 plan, targeting an expansion to Rs. 1000 crores by 2030.

Financial Performance

KAL's financial results for the half-year ended September 30 showcase performance across various business segments:

Metric	Amount (Rs. in crores)	Growth
Revenue	74.62	27%
Adjusted EBITDA	4.40	Positive

The company maintained a positive adjusted EBITDA of Rs. 4.40 crores, despite continued investments in talent, marketing, and infrastructure.

Segment-wise Performance

Kerala Ayurveda reported growth across its key business segments:

Segment	Growth
India E-commerce	50%
US Wellness Centres	82%

Additionally, the company has expanded its global footprint with the addition of a new clinic business in Singapore.

Vision 2030: Scaling New Heights

Kerala Ayurveda has unveiled its Vision 2030 plan, setting targets for the coming years:

Overall Target: Aim for revenues of Rs. 1000 crores by 2030
Global E-Product Business: Target 20x growth
Health Services Business: Aim for 10x growth

Management Commentary

Dr. K. Anilkumar, Executive Director of Kerala Ayurveda Limited, stated in the company's financial report, "The company has demonstrated strong performance across key business segments, particularly in India E-commerce and US Wellness centres. Our Vision 2030 plan sets ambitious targets that reflect our confidence in the growing demand for Ayurvedic products and services globally."

Future Outlook

Kerala Ayurveda's performance in H1 and its Vision 2030 plan indicate the company's commitment to growth and expansion in the Ayurvedic healthcare sector. The focus on scaling up its global E-Product business and Health Services business suggests an approach to capturing larger market share both domestically and internationally.

As the company continues to invest in talent, marketing, and infrastructure, it aims to capitalize on the interest in Ayurvedic and natural healthcare solutions. The addition of the Singapore clinic business also signals Kerala Ayurveda's intent to expand its international presence.

Investors and industry observers may be watching Kerala Ayurveda's progress as it works towards its Vision 2030 goals, particularly in light of the evolving global healthcare landscape and consumer interest in alternative and traditional medicine.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.39%	-9.94%	-13.51%	-24.90%	+7.68%	+596.79%

Kerala Ayurveda , a prominent player in the Ayurveda sector, has released its financial results for the second quarter of fiscal year 2025, revealing a mixed performance with increased revenue but widening losses.

Key Financial Highlights

Particulars (in Rs. Lakhs)	Q2 FY2025	Q1 FY2025	QoQ Change
Consolidated Revenue	3,483.85	2,861.16	+21.76%
Standalone Net Loss	540.06	-	-
Consolidated Net Loss	635.94	202.76*	+213.64%

*Q1 FY2025 showed a profit

Revenue Growth and Operational Performance

Kerala Ayurveda demonstrated strong top-line growth in Q2 FY2025, with consolidated revenue increasing to Rs. 3,483.85 lakhs from Rs. 2,861.16 lakhs in the previous quarter, marking a 21.76% quarter-on-quarter growth. This growth indicates robust demand for the company's Ayurvedic products and services.

Profitability Challenges

Despite the revenue growth, the company faced significant profitability challenges:

Standalone Performance: Kerala Ayurveda reported a standalone net loss of Rs. 540.06 lakhs for Q2 FY2025.
Consolidated Results: On a consolidated basis, the company's performance declined further, with a net loss of Rs. 635.94 lakhs, compared to a profit of Rs. 202.76 lakhs in Q1 FY2025.

Balance Sheet and Cash Flow

As of September 30, 2025, Kerala Ayurveda's financial position showed:

Total assets of Rs. 13,545.80 lakhs
Cash and cash equivalents of Rs. 490.98 lakhs
Total equity of Rs. 900.98 lakhs

Management Approval and Audit Status

The Board of Directors approved these unaudited financial results on November 14, 2025. The company's statutory auditors have completed a limited review of the results, as required by SEBI regulations.

Segment Information

Kerala Ayurveda operates in a single business segment - Ayurveda Business - as per Ind AS 108 on "Operating Segments."

Outlook

While Kerala Ayurveda has shown strong revenue growth, the significant increase in losses poses challenges. The company may need to focus on cost management and operational efficiency to improve its bottom line in the coming quarters.

Note: All financial figures are based on the unaudited consolidated results for the quarter ended September 30, 2025, as approved by the company's Board of Directors.